The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg

被引：0

作者：

Bocci, A. ^{[1
]}

Spielniann, D. ^{[1
]}

Azzini, Pr ^{[1
]}

Guaschino, Pr ^{[1
]}

Affronti, G. ^{[1
]}

Villani, Pr ^{[1
]}

Boselli, Pr ^{[1
]}

Genazzani, Pr ^{[1
]}

Flamigni, Z. C. ^{[1
]}

Omodei, U. ^{[1
]}

Bolis, P. ^{[1
]}

Marsoni, V. ^{[1
]}

Luerti, M. ^{[1
]}

Simenel, J. L. ^{[1
]}

Ouvry-Neveu, B. ^{[1
]}

Andre, G. ^{[1
]}

David, S. ^{[1
]}

Durand, J. L. ^{[1
]}

Ehret-Mentre, C. ^{[1
]}

Gensburger, J. M. ^{[1
]}

Goetzmann, P. ^{[1
]}

Jung-Faerber, S. ^{[1
]}

Keller, D. ^{[1
]}

Lempereur, M. ^{[1
]}

Plumere, C. ^{[1
]}

Spielmann, A. ^{[1
]}

Katz, J. L. ^{[1
]}

Sebaoun, J. ^{[1
]}

Belaisch, J. ^{[1
]}

Hammer, F. ^{[1
]}

Salama, B. ^{[1
]}

Aissaoui, S. ^{[1
]}

Taube, A. M. ^{[1
]}

Nakache, H. ^{[1
]}

Soria, J. ^{[1
]}

Joffo, M. ^{[1
]}

Lardenois, H. ^{[1
]}

Leclerc, P. ^{[1
]}

Ponsar, C. ^{[1
]}

Saubry-Bobet, V. ^{[1
]}

Blaiset, E. ^{[1
]}

Veyres, F. ^{[1
]}

Clamp, M. ^{[1
]}

Menon, K. V. K. ^{[1
]}

Moran, D. G. ^{[1
]}

Randall, S. ^{[1
]}

Shaw, P. J. ^{[1
]}

Bruni, V. ^{[1
]}

Massobrio, M. ^{[1
]}

Crosignani, P. ^{[1
]}

机构：

[1] Wyeth Ayersr Res, F-92031 Paris, France

来源：

EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE | 1999年 / 4卷

关键词：

Oral contraceptive; Contraceptive efficacy; Gestodene; Ethinylestradiol;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective The safety and contraceptive efficacy of a new 24-day regimen of an oral contraceptive combination containing gestodene (GTD) 60 mu g and ethinylestradiol (EE) 15 mu g was evaluated in an open-label, multicenter study. Methods Adult women received GTD 60 mu g/EE 15 mu g from day 1 to 24 and 4 days of placebo during a 28-day cycle for either 13 or 19 cycles. Results Of the 1515 subjects enrolled, 1496 were included in the intent-to-treat analysis. A total of three pregnancies were reported during the 18 194 treatment cycles of the study, yielding a Pearl index of 0.21. Life-table analysis, based on 16 954 cycles, gave an accidental pregnancy rate of 0.0033. The most frequent adverse events were headache (reported in 35% of subjects), absence of bleeding (16%), flu-like syndrome (15%), pharyngitis (15%) and abdominal pain (15%). The most frequent reasons for withdrawal from the study were metrorrhagia, flu syndrome and absence of bleeding. Analyses of withdrawal and intermenstrual bleeding and spotting indicated acceptable cycle control. Conclusions The 24-day GTD 60 mu g/EE 15 mu g, regimen appears to be a well-tolerated and effective method for low-dose oral contraception. The current formulation offers an ultra-low steroidal dosage combined with a reduced pill-free interval to improve contraceptive efficacy.

引用

页码：9 / 15

页数：7

共 50 条

[41] Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive
Westhoff, Carolyn L.
Hait, Howard I.
Reape, Kathleen Z.
CONTRACEPTION, 2012, 85 (03) : 235 - 239
[42] Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis
Koltun, William
Maloney, J. Michael
Marr, Joachim
Kunz, Michael
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 155 (02) : 171 - 175
[43] A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 μg ethinylestradio1/75 μg gestodene (Meliane) and 30 μg ethinylestradio1/75 μg gestodene (Gynera®)
Taneepanichskul, S
Kriengsinyot, R
Jaisamrarn, U
CONTRACEPTION, 2002, 66 (06) : 407 - 409
[44] Body weight change during use of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake
Endrikat, J
Gerlinger, C
Cronin, M
Wessel, J
Ruebig, A
Rosenbaum, P
Düsterberg, B
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2001, 6 (04): : 199 - 204
[45] The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users
Creinin, Mitchell D.
Angulo, Alicyoy
Colli, Enrico
Archer, David F.
CONTRACEPTION, 2023, 128
[46] Using a low-dose contraceptive in women 35 years of age and over:: 20 μg estradiol/100 μg levonorgestrel
Carr, BR
DelConte, A
CONTRACEPTION, 2002, 65 (06) : 397 - 402
[47] An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive
Akin, M
Archer, D
Berga, S
Burns, L
Calkins, J
Davis, A
Draeger, M
Freidensen, H
Funk, S
Giesler, C
Gordon, S
Katz, D
Khairi, S
Ledger, W
Lenihan, J
London, R
McQuarrie, H
Medina, H
Mercer, L
Milhalov, L
Montgomery, M
Notelovitz, M
Parker, G
Phillips, E
Reza, L
San Fillippo, J
Saxena, B
Singh, M
Soltes, B
Soper, H
Speroff, L
Summers, P
Trupin, S
Weissberg, S
Willems, J
Young, R
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) : S2 - S8
[48] Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial
Hadji, Peyman
Neulen, Joseph
Schaudig, Katrin
Schwenkhagen, Anneliese
Grimmbacher, Stefanie
Wiegratz, Inka
GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (06) : 513 - 520
[49] 12 YEARS OF CLINICAL-EXPERIENCE WITH AN ORAL-CONTRACEPTIVE CONTAINING 30-MU-G ETHINYLESTRADIOL AND 150-MU-G DESOGESTREL
FOTHERBY, K
CONTRACEPTION, 1995, 51 (01) : 3 - 12
[50] Added Benefits and User Satisfaction with a Low-Dose Oral Contraceptive Containing DrospirenoneResults of Three Multicentre Trials
Johannes Bitzer
Anna M. Paoletti
Clinical Drug Investigation, 2009, 29 : 73 - 78

← 1 2 3 4 5 →